Fred Hutchinson Cancer Center

Overview

The Fred Hutchinson Cancer Center is a leading cancer research institution dedicated to improving the prevention and treatment of cancer and related diseases. Known for its cutting-edge research and innovative clinical trials, the center strives to transform the future of cancer care.

Therapeutic areas

API / Drug Master Files

Fred Hutchinson Cancer Center holds 1 active (6 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• MURINE MONOCLONAL ANTIBODY (BC8) TO CD45Active2000-09-18
• B9E9SCFV4-SA FUSION PROTEINInactive2015-10-19
• MANUFACTURE AND QUALITY CONTROL OF THE BC8-DOTA MONOCLONAL ANTIBODY CONJUGATE (BC8-DOTA)Inactive2011-03-01
• BC8-SA MONOCLONAL ANTIBODY CONJUGATE (BC8-SA)Inactive2008-11-21
• MURINE MONOCLONAL ANTIBODY (9.3) TO CD-28Inactive2003-09-15
• HUMAN MONOCLONAL ANTIBODY (ABX-MA1) TO MUC-18Inactive2001-12-20

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Fred Hutchinson Cancer Center in our records. PharmaTek screens the full directory against live FDA enforcement data.